YC
DXCM icon

Yarbrough Capital’s DexCom DXCM Stock Holding History

Yarbrough Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,787
Closed -$217K – 200
2024
Q4 		$217K Buy
+2,787
New +$206K 0.01% 184
2024
Q3 		– Sell
-11,725
Closed -$1.33M – 205
2024
Q2 		$1.33M Hold
11,725
– – 0.06% 79
2024
Q1 		$1.63M Buy
11,725
+2,787
+31% +$350K 0.07% 78
2023
Q4 		$1.11M Hold
8,938
– – 0.06% 89
2023
Q3 		$834K Hold
8,938
– – 0.05% 99
2023
Q2 		$1.15M Hold
8,938
– – 0.07% 87
2023
Q1 		$1.04M Hold
8,938
– – 0.08% 89
2022
Q4 		$1.01M Sell
8,938
-3,060
-26% -$336K 0.08% 82
2022
Q3 		$966K Buy
11,998
+4,694
+64% +$398K 0.08% 84
2022
Q2 		$544K Sell
7,304
-884
-11% -$80.7K 0.04% 104
2022
Q1 		$1.05M Buy
8,188
+884
+12% +$96.7K 0.06% 96
2021
Q4 		$980K Buy
+7,304
New +$1.05M 0.05% 113

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Yarbrough Capital's DXCM Position: Q1 2025 in Review

Yarbrough Capital sold out of DexCom (DXCM) in Q1 2025, closing a stake of 2,787 shares — an estimated $217K sold.

Yarbrough Capital first reported a position in DXCM in Q4 2021 and held it in 12 quarters. The position peaked at $1.63M in Q1 2024. 932 funds tracked by Wall St. Rank hold DXCM as of Q1 2025.

  • Yarbrough Capital reported no remaining DexCom position as of Q1 2025 after selling out during the quarter.
  • Yarbrough Capital sold 2,787 DexCom shares in Q1 2025, an estimated $217K.
  • Yarbrough Capital first reported a position in DexCom in Q4 2021 and held it in 12 quarters.
  • Yarbrough Capital's DexCom position peaked at $1.63M in Q1 2024.
  • 932 funds tracked by Wall St. Rank held DexCom as of Q1 2025.

Based on Yarbrough Capital's 13F filing for Q1 2025, filed 14 Apr 2025.